Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATTNYSEARCA:BRWNYSE:SNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/ABRWSaba Capital Income & Opportunities Fund$7.87+0.3%$7.59$6.86▼$8.04N/AN/A171,834 shs502,284 shsSNNSmith & Nephew SNATS$28.80+0.8%$28.28$23.69▼$31.72$12.63B0.68808,984 shs1.49 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%BRWSaba Capital Income & Opportunities Fund0.00%+0.38%+4.79%+1.16%+12.91%SNNSmith & Nephew SNATS0.00%-1.79%+1.55%+2.58%+14.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS3.263 of 5 stars1.03.02.50.03.90.04.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/ABRWSaba Capital Income & Opportunities Fund 0.00N/AN/AN/ASNNSmith & Nephew SNATS 2.00Hold$28.00-2.77% DownsideCurrent Analyst Ratings BreakdownLatest ANII, BRW, ATT, and SNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025SNNSmith & Nephew SNATSCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$27.00 ➝ $28.004/25/2025SNNSmith & Nephew SNATSHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/25/2025SNNSmith & Nephew SNATSHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$5.81B2.17$3.15 per share9.13$12.04 per share2.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$412M$2.1613.3314.400.89N/AN/AN/A8/5/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$0.893.09%N/A41.20%N/ALatest ANII, BRW, ATT, and SNN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/3/2025BRWSaba Capital Income & Opportunities Fundmonthly$0.085013.3%6/10/20256/10/20256/30/20255/2/2025BRWSaba Capital Income & Opportunities Fundmonthly$0.085013.5%5/9/20255/9/20255/30/20254/2/2025BRWSaba Capital Income & Opportunities Fundmonthly$0.085013.1%4/9/20254/9/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATTAbattis BioceuticalsN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/ASNNSmith & Nephew SNATS0.622.891.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/ABRWSaba Capital Income & Opportunities FundN/ASNNSmith & Nephew SNATS25.64%Insider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/ABRWSaba Capital Income & Opportunities FundN/ASNNSmith & Nephew SNATS1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableBRWSaba Capital Income & Opportunities FundN/AN/AN/ANot OptionableSNNSmith & Nephew SNATS17,349437.97 million433.59 millionOptionableANII, BRW, ATT, and SNN HeadlinesRecent News About These CompaniesSmith+Nephew Stock May Gain From Strategic Deal With Standard HealthJune 20 at 12:41 PM | zacks.comSmith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UKJune 18, 2025 | globenewswire.comSmith & Nephew plc (NYSE:SNN) Sees Significant Increase in Short InterestJune 16, 2025 | marketbeat.comLorne Steinberg Wealth Management Inc. Boosts Position in Smith & Nephew plc (NYSE:SNN)June 16, 2025 | marketbeat.comPark Avenue Securities LLC Acquires Shares of 9,206 Smith & Nephew plc (NYSE:SNN)June 16, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Receives Consensus Recommendation of "Hold" from BrokeragesJune 14, 2025 | americanbankingnews.comSmith & Nephew plc (NYSE:SNN) Given Average Recommendation of "Hold" by BrokeragesJune 14, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Shares Purchased by GAMMA Investing LLCJune 13, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes Position in Smith & Nephew plc (NYSE:SNN)June 10, 2025 | marketbeat.comNew medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatilityJune 9, 2025 | globenewswire.comClean Yield Group Sells 150,568 Shares of Smith & Nephew plc (NYSE:SNN)June 8, 2025 | marketbeat.comSmith & Nephew (SN) Receives a Buy from CitiJune 7, 2025 | theglobeandmail.comSmith & Nephew plc (NYSE:SNN) Shares Purchased by NBC Securities Inc.June 6, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Short Interest Up 22.9% in MayJune 4, 2025 | marketbeat.comBank of America Corp DE Sells 266,704 Shares of Smith & Nephew plc (NYSE:SNN)June 1, 2025 | marketbeat.comSmith & Nephew SNATS, Inc. Common Stock (SNN)May 31, 2025 | nasdaq.comVident Advisory LLC Grows Stock Holdings in Smith & Nephew plc (NYSE:SNN)May 28, 2025 | marketbeat.comSmith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of DefenseMay 27, 2025 | globenewswire.comBNP Paribas Financial Markets Buys Shares of 17,709 Smith & Nephew plc (NYSE:SNN)May 27, 2025 | marketbeat.comBarrow Hanley Mewhinney & Strauss LLC Reduces Holdings in Smith & Nephew plc (NYSE:SNN)May 25, 2025 | marketbeat.comQuantinno Capital Management LP Has $2.40 Million Holdings in Smith & Nephew plc (NYSE:SNN)May 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe PayoutsThese 3 Stocks Could Be Back in Play Before You Know ItBy Gabriel Osorio-Mazilli | June 10, 2025View These 3 Stocks Could Be Back in Play Before You Know ItThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideANII, BRW, ATT, and SNN Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.Saba Capital Income & Opportunities Fund NYSEARCA:BRW$7.87 +0.02 (+0.25%) As of 06/20/2025 04:10 PM EasternSaba Capital Income & Opportunities Fund is a closed-ended fixed income mutual fund launched by Voya Investment Management LLC. The fund is managed by Saba Capital Management, L.P. It invests in the fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in floating rate secured senior loans, with an emphasis on top-tier, non-investment grade senior loans. The fund seeks to invest in loans with maturities of one to ten years. It benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index. The fund was formerly known as Voya Prime Rate Trust. Saba Capital Income & Opportunities Fund was formed on December 2, 1987 and is domiciled in the United States.Smith & Nephew SNATS NYSE:SNN$28.80 +0.22 (+0.77%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$28.82 +0.02 (+0.06%) As of 06/20/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
